Home › Research › Treatments
Clinical Role of Brain PET in Alzheimer Disease in the Era of Disease-Modifying Therapies
Ana Marija Franceschi, Graham Keir, Tammie L.S. Benzinger, Petrice M. Cogswell, Farzana Zulfiqar Ali, Jeffrey R. Petrella, Jeffrey W. Prescott, Christopher T. Whitlow et al.. American Journal of Neuroradiology, 2025-07-10
Topic: Amyloid, tau and blood-test diagnosis
Plain-language summary
Alzheimer disease (AD) is the leading cause of dementia, with an estimated 6.9 million Americans aged 65 and older living with Alzheimer dementia today, with this number projected to grow to 13.8 million by 2060. Amyloid and τ accumulation underpin our understanding of the pathophysiology of AD, with the abnormal accumulation of these proteins leading to neurodegeneration. With the recent approval of antiamyloid monoclonal antibody therapies for patients with early-stage Alzheimer disease by the Food and Drug Administration, there is renewed energy and focus on brain imaging for diagnosis, triage, and monitoring of patients with neurodegenerative disease. Furthermore, PET imaging of amyloid and τ has revolutionized our understanding of dementia progression and staging, and influences patient management in the clinical setting. We aim to update radiologists on the evolving role of amyloid and τ PET in clinical practice, emphasizing the need for standardized workflows and the integration of molecular imaging data with other disease biomarkers. We also discuss the clinical implications of amyloid and τ PET, including their impact on diagnosis and treatment decisions, as well as the challenges of reimbursement and workforce capacity. With recent shifts in the AD management landscape, it is crucial for radiologists to keep abreast of recent advances in clinical practice, thereby ensuring effective patient care.
What this study adds
Evidence grade: Low
This article describes how amyloid and tau PET imaging is used for diagnosis, triage, and monitoring of patients with neurodegenerative disease, especially after approval of anti-amyloid monoclonal antibody therapies for early-stage Alzheimer disease. It focuses on the evolving role of imaging in clinical practice, including challenges of reimbursement and workforce capacity.
Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Franceschi, A. M., Keir, G., Benzinger, T. L., Cogswell, P. M., Ali, F. Z., Petrella, J. R., et al. (2025). Clinical Role of Brain PET in Alzheimer Disease in the Era of Disease-Modifying Therapies. American Journal of Neuroradiology. https://doi.org/10.3174/ajnr.a8738
Vancouver
Franceschi AM, Keir G, Benzinger TL, Cogswell PM, Ali FZ, Petrella JR, et al. Clinical Role of Brain PET in Alzheimer Disease in the Era of Disease-Modifying Therapies. American Journal of Neuroradiology. 2025. doi:10.3174/ajnr.a8738. PMID: 40639970.
BibTeX
@article{franceschi2025-40639970,
author = {Franceschi, Ana Marija and Keir, Graham and Benzinger, Tammie L.S. and Cogswell, Petrice M. and Ali, Farzana Zulfiqar and Petrella, Jeffrey R. and Prescott, Jeffrey W. and Whitlow, Christopher T. and others},
title = {{Clinical Role of Brain PET in Alzheimer Disease in the Era of Disease-Modifying Therapies}},
journal = {American Journal of Neuroradiology},
year = {2025},
doi = {10.3174/ajnr.a8738},
pmid = {40639970},
url = {https://doi.org/10.3174/ajnr.a8738}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record's author list ends in “et al.”, so not every author is named. Check the citation against the original before you use it.
Key findings
- With the recent approval of antiamyloid monoclonal antibody therapies for patients with early-stage Alzheimer disease by the Food and Drug Administration, there is renewed energy and focus on brain imaging for diagnosis, triage, and monitoring of patients with neurodegenerative disease.
- Furthermore, PET imaging of amyloid and τ has revolutionized our understanding of dementia progression and staging, and influences patient management in the clinical setting.
- We aim to update radiologists on the evolving role of amyloid and τ PET in clinical practice, emphasizing the need for standardized workflows and the integration of molecular imaging data with other disease biomarkers.
- We also discuss the clinical implications of amyloid and τ PET, including their impact on diagnosis and treatment decisions, as well as the challenges of reimbursement and workforce capacity.
- With recent shifts in the AD management landscape, it is crucial for radiologists to keep abreast of recent advances in clinical practice, thereby ensuring effective patient care.
Why it matters
This article describes how amyloid and tau PET imaging is used for diagnosis, triage, and monitoring of patients with neurodegenerative disease, especially after approval of anti-amyloid monoclonal antibody therapies for early-stage Alzheimer disease. It focuses on the evolving role of imaging in clinical practice, including challenges of reimbursement and workforce capacity.
New to this subject? Start with our plain-English guide: Treatments →
Study details
- Evidence strengthLow
How this study scored 42/100
Published in a peer-reviewed journal. Scored zero for study design, sample size, effect reported, studied in people and randomized / blinded because the record does not state it. We have no data on senior author's track record, so that was left out: it earned 40 of the 96 points we could judge it on, which is 42 out of 100.
| Component | Points | Why |
|---|---|---|
| Journal tier | 7 / 10 | Tier 3 — peer-reviewed journal (American Journal of Neuroradiology) |
| Journal's citation record | 2 / 4 | American Journal of Neuroradiology: journal h-index 182 (OpenAlex, 2026-10-29) |
| Study design | 0 / 12 | No study design recorded — scores zero, not guessed (not stated in the record — scored 0) |
| Strength of evidence | 1 / 5 | Rated “low” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 4 / 5 | 2025 — within 3 year(s) of the newest study here |
| Sample size | 0 / 4 | Participant count not stated — scores zero (not stated in the record — scored 0) |
| Effect reported | 0 / 3 | No effect size reported — scores zero (not stated in the record — scored 0) |
| Studied in people | 0 / 3 | Not stated whether this was studied in people — scores zero (not stated in the record — scored 0) |
| Randomized / blinded | 0 / 2 | No randomization or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | 1 / 7 | Cited 3 times (OpenAlex, 2026-10-10) |
| Citations per year | 1 / 5 | 1.0 citations a year over 3 year(s) since 2025 |
| Impact for its field and year | 2 / 6 | Cited 1.9× the average for papers of its field and year (OpenAlex FWCI) |
| Cited by studies here | 1 / 6 | Cited by 1 other studies in this library |
| Still being cited | 1 / 4 | Cited 3 times in 2024–2026 (2026 still in progress; OpenAlex) |
| Senior author's track record | — / 4 | Senior author's record not available — left out of this score |
| Institution's track record | 3 / 3 | Stanford University: institution h-index 2,684 (OpenAlex) |
| Multicenter collaboration | 3 / 3 | OpenAlex lists 16 institution(s) in 1 country |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 40639970) |
| Free to read | 2 / 2 | Free to read |
| Points | 40 / 96 | Scored on 19 of 20 parts. We have no data for the rest, so they are left out: 40 of the 96 points we could judge it on is 42 out of 100. |
| Total | 42 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
- DOI: 10.3174/ajnr.a8738
- PubMed: 40639970
- Original source →
- Free full text: American Journal of Neuroradiology →
Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).
Related
Studies in the library that share something with this one. The line above each title says what.
Studies this one cites
Referenced by this study and also in the alzhub library, so you can read them here. Showing 12 of 31.
Later studies that cite this one
1 study in the alzhub library lists this one in its references.
Related studies in Treatments from nearby years
Also tagged “machine”
834 studies in the library carry the topic tag “machine”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 834 tagged studies.